This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

2 Jun 2020

AGC Biologics acquires AstraZeneca commercial biomanufacturing facility

The Boulder, Colorado, USA facility will increase global capacity and extend manufacturing scale.

AGC Biologics, a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has purchased a state-of-the-art commercial manufacturing facility — formerly owned by AstraZeneca — in Boulder, Colorado, USA.

The large-scale biopharmaceutical manufacturing facility houses two 20,000-L (total volume) stainless steel mammalian cell bioreactors. It also has more than 20 acres with multiple opportunities for future expansions, including space for up to four more 20,000-L bioreactors. The automated facility is particularly well suited for high volume commercial production and high titer antibody processes.

AGC Biologics is rapidly expanding its customer portfolio, including a higher ratio of late-phase and commercial projects, as well as advancing current projects into the commercial phase. This addition to their facility network will enable the company to support a wider range of commercial demand.

In addition to this facility acquisition, AGC Biologics is completing major facility expansion projects at its Seattle, Copenhagen and Chiba facilities in 2020 and early 2021. The facility is expected to begin full-scale operations and manufacturing by April 2021.

Related News